Vaccines against SARS-CoV-2 variants and future pandemics

References

• Finkel Y, Mizrahi O, Nachshon A, et al. The coding capacity of SARS-CoV-2. Nature. 2021;589(7840):125–130.
   PubMed Web of Science ®Google Scholar
• Lai MM, Stohlman SA. Comparative analysis of RNA genomes of mouse hepatitis viruses. J Virol. 1981 May;38(2):661–670.
   PubMed Web of Science ®Google Scholar
• Yogo Y, Hirano N, Hino S, et al. Polyadenylate in the virion RNA of mouse hepatitis virus. J Biochem. 1977;82(4):1103–1108.
   PubMed Web of Science ®Google Scholar
• Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020;10:317.
   PubMed Web of Science ®Google Scholar
• Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134.
   PubMed Web of Science ®Google Scholar
• Simmons G, Gosalia DN, Rennekamp AJ, et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A. 2005;102(33):11876–11881.
   PubMed Web of Science ®Google Scholar
• Sun G, Sui Y, Zhou Y, et al. Structural basis of covalent inhibitory mechanism of TMPRSS2-Related serine proteases by camostat. J Virol. 2021;95(19):e0086121.
   PubMed Web of Science ®Google Scholar
• Li T, Han X, Gu C, et al. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. Nat Commun. 2021;12(1):6304.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Cao D, Zhang Y, et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat Commun. 2017;10(8):15092.
   Google Scholar
• Gui M, Song W, Zhou H, et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 2017;27(1):119–129.
   PubMed Web of Science ®Google Scholar
• Berger I, Schaffitzel C. The SARS-CoV-2 spike protein: balancing stability and infectivity. Cell Res. 2020 Dec;30(12):1059–1060.
   PubMed Web of Science ®Google Scholar
• Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727–11734.
   PubMed Web of Science ®Google Scholar
• Ma Q, Liu J, Liu Q, et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and meta-analysis. JAMA Network Open. 2021;4(12):e2137257.
   PubMed Web of Science ®Google Scholar
• Klinakis A, Cournia Z, Rampias T. N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains. Comput Struct Biotechnol J. 2021;19:5556–5567.
   Web of Science ®Google Scholar
• Wang R, Chen J, Gao K, et al. Analysis of SARS-CoV-2 mutations in the United States suggests presence of four substrains and novel variants. Commun Biol. 2021;4(1):228.
   PubMed Web of Science ®Google Scholar
• Sriram K, Insel PA. A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance. Br J Pharmacol. 2020 Nov;177(21):4825–4844.
   PubMed Web of Science ®Google Scholar
• Geranmayeh MH, Rahbarghazi R, Farhoudi M. Targeting pericytes for neurovascular regeneration. Cell Commun Signal. 2019;17(1):26.
   PubMedGoogle Scholar
• Fagiani E, Christofori G. Angiopoietins in angiogenesis. Cancer Lett. 2013;328(1):18–26.
   PubMed Web of Science ®Google Scholar
• Cure E, Cumhur Cure M, Vatansev H. Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension. J Renin Angiotensin Aldosterone Syst. 2020;21(4):1470320320972015.
   Web of Science ®Google Scholar
• Saheb Sharif-Askari N, Saheb Sharif-Askari F, Alabed M, et al. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol Ther Methods Clin Dev. 2020;18:1–6.
   PubMed Web of Science ®Google Scholar
• Yanez ND, Weiss NS, Romand JA, et al. COVID-19 mortality risk for older men and women. BMC Public Health. 2020;20(1):1742.
   PubMed Web of Science ®Google Scholar
• Uhlen M, Fagerberg L, Hallstrom BM, et al. Tissue-based map of the human proteome. Science 2015; 347(6220):1260419. Proteomics
   PubMed Web of Science ®Google Scholar
• Li W, Qiao J, You Q, et al. SARS-CoV-2 Nsp5 activates NF-kappaB pathway by upregulating SUMOylation of MAVS. Front Immunol. 2021;12:750969.
   PubMed Web of Science ®Google Scholar
• Sampaio NG, Chauveau L, Hertzog J, et al. The RNA sensor MDA5 detects SARS-CoV-2 infection. Sci Rep. 2021;11(1):13638.
   PubMed Web of Science ®Google Scholar
• Yin X, Riva L, Pu Y, et al. MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep. 2021;34(2):108628.
   PubMed Web of Science ®Google Scholar
• Yang DM, Geng TT, Harrison AG, et al. Differential roles of RIG-I like receptors in SARS-CoV-2 infection. Mil Med Res. 2021;8(1):49.
   PubMed Web of Science ®Google Scholar
• Yamada T, Sato S, Sotoyama Y, et al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat Immunol. 2021;22(7):820–828.
   PubMed Web of Science ®Google Scholar
• Li N, Hui H, Bray B, et al. METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection. Cell Rep. 2021;35(6):109091.
   PubMed Web of Science ®Google Scholar
• Loo YM, Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity. 2011;34(5):680–692.
   PubMed Web of Science ®Google Scholar
• Zheng M, Karki R, Williams EP, et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021;22(7):829–838.
   PubMed Web of Science ®Google Scholar
• Theobald SJ, Simonis A, Georgomanolis T, et al. Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. EMBO Mol Med. 2021;13(8):e14150.
   PubMed Web of Science ®Google Scholar
• Schlee M, Hartmann G. Discriminating self from non-self in nucleic acid sensing. Nat Rev Immunol. 2016 Sep;16(9):566–580.
   PubMed Web of Science ®Google Scholar
• Salvi V, Nguyen HO, Sozio F, et al. SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8. JCI Insight. 2021;6:18.
   Web of Science ®Google Scholar
• Campbell GR, To RK, Hanna J, et al. SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway. iScience. 2021;24(4):102295.
   PubMed Web of Science ®Google Scholar
• Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20(3):319–325.
   PubMed Web of Science ®Google Scholar
• Madden EA, Diamond MS. Host cell-intrinsic innate immune recognition of SARS-CoV-2. Curr Opin Virol. 2022 Feb;52:30–38.
   PubMed Web of Science ®Google Scholar
• Siu KL, Yuen KS, Castano-Rodriguez C, et al. Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. FASEB J. 2019;33(8):8865–8877.
   PubMed Web of Science ®Google Scholar
• Nieto-Torres JL, Verdia-Baguena C, Jimenez-Guardeno JM, et al. Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology. 2015;485:330–339.
   PubMed Web of Science ®Google Scholar
• Shah A. Novel coronavirus-induced NLRP3 inflammasome activation: a potential drug target in the treatment of COVID-19. Front Immunol. 2020;11:1021.
   PubMed Web of Science ®Google Scholar
• Glenting J, Wessels S. Ensuring safety of DNA vaccines. Microb Cell Fact. 2005 Sep;6(4):26.
   Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
   PubMed Web of Science ®Google Scholar
• Shafaati M, Saidijam M, Soleimani M, et al. A brief review on DNA vaccines in the era of COVID-19. Future Virol. 2021. DOI:10.2217/fvl-2021-0170.
   PubMed Web of Science ®Google Scholar
• Hwang HS, Kwon YM, Lee JS, et al. Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antiviral Res. 2014;110:115–123.
   PubMed Web of Science ®Google Scholar
• Mallapaty S. India’s DNA COVID vaccine is a world first - more are coming. Nature. 2021 Sep;597(7875):161–162.
   PubMed Web of Science ®Google Scholar
• Fu Y, Fang Y, Lin Z, et al. Inhibition of cGAS-Mediated interferon response facilitates transgene expression. iScience. 2020;23(4):101026.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399(10321):237–248.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020 Oct;586(7830):516–527.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681.
   PubMed Web of Science ®Google Scholar
• van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586(7830):578–582.
   PubMed Web of Science ®Google Scholar
• Mercado NB, Zahn R, Wegmann F, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583–588.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–1829.
   PubMed Web of Science ®Google Scholar
• Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–1555.
   PubMed Web of Science ®Google Scholar
• Laczko D, Hogan MJ, Toulmin SA, et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against sARS-CoV-2 in mice. Immunity. 2020;53(4):724–732 e7.
   PubMed Web of Science ®Google Scholar
• Gruell H, Vanshylla K, Tober-Lau P, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 omicron variant. Nat Med. 2022;28:477–480.
   PubMed Web of Science ®Google Scholar
• Maugeri M, Nawaz M, Papadimitriou A, et al. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells. Nat Commun. 2019;10(1):4333.
   PubMed Web of Science ®Google Scholar
• Hou X, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094.
   PubMed Web of Science ®Google Scholar
• Park JW, Lagniton PNP, Liu Y, et al. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021;17(6):1446–1460.
   PubMed Web of Science ®Google Scholar
• Jeeva S, Kim KH, Shin CH, et al. An update on mRNA-based viral vaccines. Vaccines (Basel). 2021;9(9):1–17.
   Web of Science ®Google Scholar
• Fischer PM. Cap in hand: targeting eIF4E. Cell Cycle. 2009;8(16):2535–2541.
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–1840.
   PubMed Web of Science ®Google Scholar
• Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–175.
   PubMed Web of Science ®Google Scholar
• Jackson NAC, Kester KE, Casimiro D, et al. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11.
   PubMed Web of Science ®Google Scholar
• Presnyak V, Alhusaini N, Chen YH, et al. Codon optimality is a major determinant of mRNA stability. Cell. 2015;160(6):1111–1124.
   PubMed Web of Science ®Google Scholar
• Guan S, Rosenecker J. Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Therapy. 2017 Mar;24(3):133–143.
   PubMed Web of Science ®Google Scholar
• Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222.
   PubMed Web of Science ®Google Scholar
• Escobar A, Reyes-Lopez FE, Acevedo ML, et al. Evaluation of the immune response induced by coronaVac 28-day schedule vaccination in a healthy population group. Front Immunol. 2021;12:766278.
   PubMed Web of Science ®Google Scholar
• Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306.
   PubMed Web of Science ®Google Scholar
• Colak E, Leslie A, Zausmer K, et al. RNA and imidazoquinolines are sensed by distinct TLR7/8 ectodomain sites resulting in functionally disparate signaling events. J Immunol. 2014;192(12):5963–5973.
   PubMed Web of Science ®Google Scholar
• Haynes BF, Corey L, Fernandes P, et al. Prospects for a safe COVID-19 vaccine. Sci Transl Med. 2020;12:568.
   Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–434.
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Bottazzi ME. Whole inactivated virus and protein-based COVID-19 vaccines. Annu Rev Med. 2022 Jan;73(1):55–64.
   PubMedGoogle Scholar
• Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987;257(19):2612–2616.
   PubMed Web of Science ®Google Scholar
• Qian C, Liu X, Xu Q, et al. Recent progress on the versatility of virus-like particles. Vaccines (Basel). 2020;8:1.
   Web of Science ®Google Scholar
• Hager KJ, Perez Marc G, Gobeil P, et al. Efficacy and safety of a recombinant plant-based adjuvanted covid-19 vaccine. N Engl J Med. 2022;386(22):2084–2096.
   PubMed Web of Science ®Google Scholar
• Ward BJ, Gobeil P, Seguin A, et al. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. Nat Med. 2021;27(6):1071–1078.
   PubMed Web of Science ®Google Scholar
• Liang JG, Su D, Song TZ, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021;12(1):1346.
   PubMed Web of Science ®Google Scholar
• Richmond P, Hatchuel L, Dong M, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10275):682–694.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, et al. Phase 1-2 Trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–2332.
   PubMed Web of Science ®Google Scholar
• Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899–1909.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay L, Yadav PD, Gupta N, et al. Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian J Med Res. 2021;153(1 & 2):93–114.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.
   PubMed Web of Science ®Google Scholar
• Vogel AB, Kanevsky I, Che Y, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592(7853):283–289.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Mateus J, Coelho CH, et al. Humoral and cellular immune memory to four COVID-19 vaccines. bioRxiv. 2022;21:1–24.
   Google Scholar
• Rauch S, Roth N, Schwendt K, et al. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines. 2021;6(1):57.
   PubMed Web of Science ®Google Scholar
• Kalnin KV, Plitnik T, Kishko M, et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines. 2021;6(1):61.
   PubMed Web of Science ®Google Scholar
• Bangaru S, Ozorowski G, Turner HL, et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020;370(6520):1089–1094.
   PubMed Web of Science ®Google Scholar
• Tian JH, Patel N, Haupt R, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12(1):372.
   PubMed Web of Science ®Google Scholar
• Guebre-Xabier M, Patel N, Tian JH, et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020;38(50):7892–7896.
   PubMed Web of Science ®Google Scholar
• Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021;398(10303):856–869.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang Y, Huang B, et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. 2020;182(3):713–721 e9.
   PubMed Web of Science ®Google Scholar
• Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369(6499):77–81.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173–2184.
   PubMed Web of Science ®Google Scholar
• Sapkal GN, Yadav PD, Ella R, et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. J Travel Med. 2021;28(4):1–3.
   Web of Science ®Google Scholar
• Behera P, Singh AK, Subba SH, et al. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. Hum Vaccin Immunother. 2022;18(1):2034456.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary report. N Engl J Med. 2020;383(20):1920–1931.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck R, Falsey AR, et al. RNA-Based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv. 2020. DOI: 10.1101/2020.08.17.20176651.
   Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478.
   PubMed Web of Science ®Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):951–960.
   PubMed Web of Science ®Google Scholar
• Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80–82.
   PubMed Web of Science ®Google Scholar
• Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208.
   PubMedGoogle Scholar
• Lustig Y, Zuckerman N, Nemet I, et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Euro Surveill. 2021;26(26). DOI:10.2807/1560-7917.ES.2021.26.26.2100557.
   Google Scholar
• Shastri J, Parikh S, Aggarwal V, et al. Severe SARS-CoV-2 breakthrough reinfection with delta variant after recovery from breakthrough Infection by alpha variant in a fully vaccinated health worker. Front Med (Lausanne). 2021;8:737007.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kruger N, Schulz S, et al. The omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456 e11.
   PubMed Web of Science ®Google Scholar
• Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 omicron to antibody neutralization. Nature. 2022;602(7898):671–675.
   PubMed Web of Science ®Google Scholar
• Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–681.
   PubMed Web of Science ®Google Scholar
• Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416.
   PubMed Web of Science ®Google Scholar
• Levine-Tiefenbrun M, Yelin I, Alapi H, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. Nat Med. 2021;27(12):2108–2110.
   PubMed Web of Science ®Google Scholar
• Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. Sci Immunol. 2021;6(59). DOI:10.1126/sciimmunol.abj1750.
   PubMed Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398(10318):2258–2276.
   PubMed Web of Science ®Google Scholar
• Reynolds SL, Kaufman HW, Meyer WA, et al. Duration of protection against SARS-CoV-2 reinfection and associated risk of reinfection assessed with real-World data. medRxiv. 2022. DOI:10.1101/2022.02.25.22271515.
   Google Scholar
• Nordstrom P, Ballin M, Nordstrom A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022 Jun;22(6):781–790.
   PubMed Web of Science ®Google Scholar
• Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022;399(10325):625–626.
   PubMed Web of Science ®Google Scholar
• Rajao DS, Perez DR. Universal Vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture. Front Microbiol. 2018;9:123.
   PubMed Web of Science ®Google Scholar
• Cao M, Su X, Broad-Spectrum Anti-coronavirus JS. Vaccines and therapeutics to combat the current COVID-19 pandemic and future coronavirus Disease outbreaks. Stem Cell Reports. 2021;16(3):398–411.
   PubMed Web of Science ®Google Scholar
• Dey J, Mahapatra SR, Lata S, et al. Exploring Klebsiella pneumoniae capsule polysaccharide proteins to design multiepitope subunit vaccine to fight against pneumonia. Expert Rev Vaccines. 2022;21(4):569–587.
   PubMed Web of Science ®Google Scholar
• Mahapatra SR, Sahoo S, Dehury B, et al. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection. Expert Rev Vaccines. 2020;19(9):871–885.
   PubMed Web of Science ®Google Scholar
• Dey J, Mahapatra SR, Singh P, et al. B and T cell epitope-based peptides predicted from clumping factor protein of Staphylococcus aureus as vaccine targets. Microb Pathog. 2021;160:105171.
   PubMed Web of Science ®Google Scholar
• Mahapatra SR, Dey J, Kaur T, et al. Immunoinformatics and molecular docking studies reveal a novel Multi-Epitope peptide vaccine against pneumonia infection. Vaccine. 2021;39(42):6221–6237.
   PubMed Web of Science ®Google Scholar
• Dey J, Mahapatra SR, Patnaik S, et al. Molecular characterization and designing of a novel multiepitope vaccine construct against Pseudomonas aeruginosa. Int J Pept Res Ther. 2022;28(2):49.
   PubMed Web of Science ®Google Scholar
• Chatterjee R, Sahoo P, Mahapatra SR, et al. Development of a conserved chimeric vaccine for induction of strong immune response against staphylococcus aureus using immunoinformatics approaches. Vaccines (Basel). 2021;9(9):1–23.
   Web of Science ®Google Scholar
• Mahapatra SR, Dey J, Kushwaha GS, et al. Immunoinformatic approach employing modeling and simulation to design a novel vaccine construct targeting MDR efflux pumps to confer wide protection against typhoidal Salmonella serovars. J Biomol Struct Dyn. 2021;31:1–13.
   Google Scholar
• Sahoo S, Mahapatra SR, Parida BK, et al. DBCOVP: a database of coronavirus virulent glycoproteins. Comput Biol Med. 2021;129:104131.
   PubMed Web of Science ®Google Scholar
• Prakash S, Srivastava R, Coulon PG, et al. Genome-Wide asymptomatic B-Cell, CD4 (+) and CD8 (+) T-Cell epitopes, that are highly conserved between human and animal coronaviruses, identified from SARS-CoV-2 as immune targets for pre-emptive pan-coronavirus vaccines. bioRxiv. 2020. DOI:10.1101/2020.09.27.316018.
   PubMedGoogle Scholar
• Schmitz AJ, Turner JS, Liu Z, et al. A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. Immunity. 2021;54(9):2159–2166 e6.
   PubMed Web of Science ®Google Scholar
• Tan CW, Chia WN, Young BE, et al. Pan-Sarbecovirus neutralizing antibodies in BNT162b2-Immunized SARS-CoV-1 survivors. N Engl J Med. 2021;385(15):1401–1406.
   PubMed Web of Science ®Google Scholar
• Martinez DR, Schafer A, Leist SR, et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. 2021;373(6558):991–998.
   PubMed Web of Science ®Google Scholar
• Dangi T, Palacio N, Sanchez S, et al. Cross-protective immunity following coronavirus vaccination and coronavirus infection. J Clin Invest. 2021;131(24). DOI:10.1172/JCI151969.
   PubMed Web of Science ®Google Scholar
• Ong E, Wong MU, Huffman A, et al. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Front Immunol. 2020;11:1581.
   PubMed Web of Science ®Google Scholar
• Team CC-R, Food, Drug A. Allergic reactions including anaphylaxis after receipt of the first dose of pfizer-BioNTech COVID-19 vaccine - United States, December 14- 23,2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51.
   PubMed Web of Science ®Google Scholar
• Wang N, Shang J, Jiang S, et al. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298.
   PubMed Web of Science ®Google Scholar
• Saunders KO, Lee E, Parks R, et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021;594(7864):553–559.
   PubMed Web of Science ®Google Scholar
• Starr TN, Czudnochowski N, Liu Z, et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature. 2021;597(7874):97–102.
   PubMed Web of Science ®Google Scholar
• Cohen AA, Gnanapragasam PNP, Lee YE, et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science. 2021;371(6530):735–741.
   PubMed Web of Science ®Google Scholar
• Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020;11(1):2806.
   PubMed Web of Science ®Google Scholar
• Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722–733 e11.
   PubMed Web of Science ®Google Scholar
• Pinto D, Sauer MM, Czudnochowski N, et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science. 2021;373(6559):1109–1116.
   PubMed Web of Science ®Google Scholar
• Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020;369(6504):650–655.
   PubMed Web of Science ®Google Scholar
• Zhao J, Wang L, Schank M, et al. SARS-CoV-2 specific memory T cell epitopes identified in COVID-19-recovered subjects. Virus Res. 2021;304:198508.
   PubMed Web of Science ®Google Scholar
• Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N Engl J Med. 2022;386(13):1288–1290.
   PubMed Web of Science ®Google Scholar
• Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron in South Africa. Science. 2022;376(6593):eabn4947.
   PubMed Web of Science ®Google Scholar
• Pack SM, Peters PJ. SARS-CoV-2-specific vaccine candidates; the contribution of structural vaccinology. Vaccines (Basel). 2022;10(2). DOI:10.3390/vaccines10020236
   Web of Science ®Google Scholar
• Nathan A, Rossin EJ, Kaseke C, et al. Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell. 2021;184(17):4401–4413 e10.
   PubMed Web of Science ®Google Scholar
• Naranbhai V, Nathan A, Kaseke C, et al. T cell reactivity to the SARS-CoV-2 omicron variant is preserved in most but not all individuals. Cell. 2022;185(7):1259.
   PubMed Web of Science ®Google Scholar
• Huang HY, Liao HY, Chen X, et al. Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. Sci Transl Med. 2022;14(639):eabm0899.
   PubMed Web of Science ®Google Scholar
• Wu CY, Cheng CW, Kung CC, et al. Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine. Proc Natl Acad Sci U S A. 2022;119(9). DOI: 10.1073/pnas.2119995119.
   Web of Science ®Google Scholar